PMID- 33614236
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210223
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 23
DP  - 2021 Mar 5
TI  - Circular RNA RBPMS inhibits bladder cancer progression via miR-330-3p/RAI2 
      regulation.
PG  - 872-886
LID - 10.1016/j.omtn.2021.01.009 [doi]
AB  - Bladder cancer is a severe cancer with high mortality because of invasion and 
      metastasis. Growing evidence has revealed that circular RNAs play critical roles 
      in biological function, which is closely connected to proliferation and invasion 
      of bladder cancer. In our study, we employed qRT-PCR, RNA fluorescence in situ 
      hybridization (FISH), 5-ethynyl-2'-deoxyuridine (EdU), CCK-8, Transwell assays, 
      luciferase reporter assays, xenografts, and live imaging to detect the roles of 
      circular RNA binding protein with multiple splicing (circRBPMS) in bladder cancer 
      (BC). Bioinformatics analysis and WB were performed to investigate the regulatory 
      mechanism. Expression profile analysis of circular RNAs (circRNAs) in BC revealed 
      that circRBPMS was significantly downregulated. Low circRBPMS expression 
      correlates with aggressive BC phenotypes, whereas upregulation of circRBPMS 
      suppresses BC cell proliferation and metastasis by directly targeting the 
      miR-330-3p/ retinoic acid induced 2 (RAI2) axis. miR-330-3p upregulation or 
      silencing of RAI2 restored BC cell proliferation, invasion, and migration 
      following overexpression of circRBPMS. RAI2 silencing reversed miR-330-3p-induced 
      cell invasion and migration as well as growth inhibition in vitro. Moreover, 
      through bioinformatic analysis of the downstream target of RAI2 in the TCGA 
      database, we identified and validated the biological role of circRBPMS through 
      the RAI2-mediated ERK and epithelial-mesenchymal transition (EMT) pathways. We 
      summarize the circRBPMS/miR-330-3p/RAI2 axis, where circRBPMS acts as a tumor 
      suppressor, and provide a potential biomarker and therapeutic target for BC.
CI  - (c) 2021 The Author(s).
FAU - Yang, Chen
AU  - Yang C
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - National Clinical Research Center for Aging and Medicine, Fudan University, 
      Shanghai 200040, China.
FAU - Mou, Zezhong
AU  - Mou Z
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Zhang, Zheyu
AU  - Zhang Z
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Wu, Siqi
AU  - Wu S
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Zhou, Quan
AU  - Zhou Q
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Chen, Yiling
AU  - Chen Y
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Gong, Jian
AU  - Gong J
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Xu, Chenyang
AU  - Xu C
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Ou, Yuxi
AU  - Ou Y
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Chen, Xinan
AU  - Chen X
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Dai, Xiyu
AU  - Dai X
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Jiang, Haowen
AU  - Jiang H
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, 
      China.
AD  - National Clinical Research Center for Aging and Medicine, Fudan University, 
      Shanghai 200040, China.
LA  - eng
PT  - Journal Article
DEP - 20210116
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
PMC - PMC7868720
OTO - NOTNLM
OT  - EMT
OT  - ERK
OT  - RAI2
OT  - bladder cancer
OT  - circRBPMS
OT  - miR-330-3p
COIS- The authors declare no competing interests.
EDAT- 2021/02/23 06:00
MHDA- 2021/02/23 06:01
PMCR- 2021/01/16
CRDT- 2021/02/22 05:56
PHST- 2020/03/12 00:00 [received]
PHST- 2021/01/10 00:00 [accepted]
PHST- 2021/02/22 05:56 [entrez]
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2021/02/23 06:01 [medline]
PHST- 2021/01/16 00:00 [pmc-release]
AID - S2162-2531(21)00009-3 [pii]
AID - 10.1016/j.omtn.2021.01.009 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2021 Jan 16;23:872-886. doi: 10.1016/j.omtn.2021.01.009. 
      eCollection 2021 Mar 5.